Intra-Cellular Therapies

ITCI68

$85.69arrow_drop_up0.28%$0.23

ITCI68

$85.69

arrow_drop_up0.28%$0.23

Performance History

Key Stats
Open	$85.88
Prev. Close	$85.45
EPS	-0.87
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	84.77	90.68
52 Week Range	45.50	93.48

Ratios







EPS	-0.87

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Intra-Cellular Therapies (ITCI)

Intra-Cellular Therapies Inc (ITCI) is a biopharmaceutical company focused on the development of innovative treatments for central nervous system (CNS) disorders. The company's lead product candidate is lumateperone, a novel antipsychotic agent being evaluated for the treatment of schizophrenia and bipolar depression. Lumateperone's mechanism of action involves modulation of serotonin, dopamine, and glutamate, aiming to improve both positive and negative symptoms of these disorders.

In recent years, Intra-Cellular Therapies has made significant progress in the clinical development of lumateperone. The company successfully completed a Phase 3 clinical trial for schizophrenia, demonstrating favorable efficacy and safety profiles compared to placebo. The results supported the New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA), seeking approval for the treatment of schizophrenia in adults. Additionally, lumateperone is being evaluated in a Phase 3 clinical trial for bipolar depression.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Dr. Sharon Mates Ph.D.
Headquarters: New York
Employees: 561
Exchange: NASDAQ

add Intra-Cellular Therapies to watchlist

Keep an eye on Intra-Cellular Therapies

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Intra-Cellular Therapies 's (ITCI) price per share?

The current price per share for Intra-Cellular Therapies (ITCI) is $85.69. The stock has seen a price change of $0.24 recently, indicating a 0.28% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Intra-Cellular Therapies (ITCI)?

For Intra-Cellular Therapies (ITCI), the 52-week high is $93.48, which is 9.09% from the current price. The 52-week low is $45.5, the current price is 88.33% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Intra-Cellular Therapies (ITCI) a growth stock?

Intra-Cellular Therapies (ITCI) has shown an average price growth of -3.66% over the past three years. It has received a score of 78 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Intra-Cellular Therapies as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Intra-Cellular Therapies (ITCI) stock price performance year to date (YTD)?

As of the latest data, Intra-Cellular Therapies (ITCI) has a year-to-date price change of 21.56%. Over the past month, the stock has experienced a price change of 13.29%. Over the last three months, the change has been 15.04%. Over the past six months, the figure is 30.74%. Looking at a longer horizon, the five-year price change stands at 829.39%.

help

Is Intra-Cellular Therapies (ITCI) a profitable company?

Intra-Cellular Therapies (ITCI) has a net income of -$139.67M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 92.73% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -22.15% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $464.37M, with a revenue growth rate of 86.4%, providing insight into the company's sales performance and growth. The gross profit is $430.62M. Operating income is noted at -$159.38M. Furthermore, the EBITDA is -$121.09M.

help

What is the market capitalization of Intra-Cellular Therapies (ITCI)?

Intra-Cellular Therapies (ITCI) has a market capitalization of $9.08B. The average daily trading volume is 85.58, indicating the stock's liquidity and investor engagement.